Wearable Cardioverter Defibrillators Market Size
The wearable cardioverter defibrillators market size reached US$ 265.26 million in 2025 and is expected to reach US$ 638.43 million by 2035, growing at a CAGR of 9.3% during the forecast period 2026-2035.
The global wearable cardioverter defibrillators market is experiencing significant growth, driven by advancements in cardiac care technology and the increasing prevalence of cardiovascular diseases. The market is also poised for substantial growth, driven by technological innovations, an aging population, and the integration of telehealth solutions. However, addressing challenges such as high costs, regulatory hurdles, and awareness gaps will be crucial for maximizing market potential. Stakeholders must focus on enhancing accessibility and education to ensure the widespread adoption of WCDs in managing sudden cardiac arrest risks.
Key Takeaways
- The market is expected to double between 2025 and 2035, supported by a sustained 9.3% CAGR.
- Implantable cardioverter defibrillators accounted for 79.84% of the product type segment in 2024, reflecting strong physician preference for permanent rhythm management.
- North America represented 42.24% of global revenue in 2024, supported by advanced healthcare infrastructure and reimbursement coverage.
- Rising global cases of sudden cardiac death, estimated at around 2 million annually, continue to strengthen demand for preventive cardiac monitoring solutions.
- Device innovation, including remote monitoring capabilities and advanced arrhythmia detection, remains a primary competitive differentiator.
- Battery performance, charging requirements, and long-term patient adherence remain important commercial considerations for manufacturers.
Market Scope
| Metric | Details |
| Market Size (2025) | US$ 265.26 Million |
| Market Forecast (2035) | US$ 638.43 Million |
| CAGR | 9.30% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | Product Type, Application, End User, Region |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
Executive Summary
For more details on this report – Request for Sample
Wearable Cardioverter Defibrillators Market Dynamics: Drivers & Restraints
The rising incidence of sudden cardiac arrest is significantly driving the wearable cardioverter defibrillators market growth
According to the National Institute of Health, around 2 million sudden cardiac death (SCD) cases are reported each year worldwide. This high incidence and the associated mortality and morbidity make sudden cardiac arrest (SCA) and SCD major global public health problems. As the incidence of sudden cardiac arrest continues to rise due to various factors like an aging population, higher cardiovascular disease rates, and increasing SCA cases, the wearable defibrillator market is expected to grow significantly. Wearable cardioverter defibrillators offer a practical, life-saving solution for high-risk individuals, fueling both demand and market expansion.
As awareness grows around conditions that lead to SCA, such as arrhythmias, congenital heart defects, or a history of heart disease, more patients and healthcare providers are recognizing the importance of wearable defibrillators as an essential preventive measure. The rise in cardiovascular diseases, especially in older populations, is leading to higher rates of SCA. For instance, athletes and individuals with hereditary conditions like Long QT Syndrome are more prone to sudden cardiac events, thus accelerating demand for wearable defibrillators.
Limited battery life and device downtime are hampering the wearable cardioverter defibrillators market growth
Wearable cardioverter defibrillators, such as ZOLL's LifeVest, require regular charging or battery replacement, typically every 24-48 hours. This frequent downtime can be inconvenient for patients, especially for those in critical conditions or living in remote areas where access to charging facilities is limited. The need for frequent recharging undermines the reliability of the device, as patients may forget or fail to recharge it in time, thus leaving them unprotected during critical moments.
As the battery reaches the end of its lifespan, it can lead to potential malfunctions or the failure of the device to deliver appropriate shocks. In high-risk cardiac patients, such failures can result in severe consequences, including death. These technical limitations reduce the perceived reliability of wearable cardioverter defibrillators, making healthcare providers and patients wary of using them over long periods.
Wearable Cardioverter Defibrillators Market Segment Analysis
The global wearable cardioverter defibrillators market is segmented based on product type, application, end-user, and region.
Product Type:
The implantable cardioverter defibrillators from the product type segment are expected to hold 79.84% of the market share in 2024 in the wearable cardioverter defibrillators market
Implantable cardioverter defibrillators offer continuous, uninterrupted protection against sudden cardiac arrest (SCA) and arrhythmias, unlike external wearable defibrillators (WCDs), which are intended as temporary solutions. Implantable cardioverter defibrillators are implanted directly into the patient’s chest and monitor heart rhythms around the clock, automatically delivering shocks when necessary. This permanent protection eliminates the need for recharging or device downtime, which is a challenge for WCDs.
Implantable cardioverter defibrillators have evolved with advanced features like leadless systems, automatic arrhythmia detection, and remote monitoring. These features make implantable cardioverter defibrillators more sophisticated, adaptable, and integrated into modern healthcare systems. In contrast, wearable defibrillators (WCDs) are limited in functionality, primarily serving as a bridge before permanent implantation.
For instance, in March 2025, Medtronic launched its Aurora EV-ICD system for treating ventricular arrhythmias in Japan. They comprise the implantable cardioverter defibrillator (ICD) system that performs electrotherapy to restore the heart to a normal rhythm. Aurora delivers defibrillation, anti-tachycardia pacing (ATP) and backup (pause-prevention) pacing therapies. It features a similar size, shape and longevity to traditional transvenous ICDs. This technology improves patient outcomes, making ICDs more desirable in managing high-risk patients.
Wearable Cardioverter Defibrillators Market Geographical Analysis
North America is expected to dominate the global wearable cardioverter defibrillators market with a 42.24% share in 2024
The high incidence of cardiovascular diseases in North America, particularly in the U.S., drives the demand for cardiac monitoring devices like wearable cardioverter defibrillators. According to the American Heart Association, heart disease remains the leading cause of death in the U.S., and conditions like arrhythmias and sudden cardiac arrest (SCA) are becoming more common due to an aging population, sedentary lifestyles, and increased rates of obesity and diabetes.
North America benefits from comprehensive insurance reimbursement systems, particularly in the U.S., which make wearable cardioverter defibrillators more accessible to patients. The widespread Medicare and private insurance coverage of wearable defibrillators has contributed significantly to their adoption, making them a viable option for patients who otherwise might not be able to afford the device.
For instance, in January 2024, Kestra Medical Technologies announced that the ASSURE Wearable Cardioverter Defibrillator (WCD) system is available to cover over 200+ million health plan members across the U.S. The company reached this covered-lives milestone less than eighteen months after commencing the national commercial launch phase of the ASSURE system in the U.S. The more than 200 million total covered lives include broad coverage for members of all national commercial insurers and many of the regional commercial insurers and networks, including Cigna, Premera, CareCentrix, Florida Blue, and multiple other Blue Cross Blue Shield (BCBS) plans.
Key Developments
June 2026: Kestra Medical Technologies expanded the commercialization of its ASSURE® Wearable Cardioverter Defibrillator (WCD) system, strengthening its market presence through broader hospital adoption and enhanced remote patient monitoring capabilities.
May 2026: ZOLL Medical Corporation introduced software enhancements for its LifeVest® Wearable Cardioverter Defibrillator, improving patient connectivity, physician monitoring, and therapy management through advanced digital health integration.
April 2026: Element Science advanced clinical evaluation of its next-generation wearable cardiac protection platform, designed to provide temporary protection against sudden cardiac arrest while improving patient comfort and compliance.
March 2026: Kestra Medical Technologies announced continued expansion of its commercial operations and healthcare provider partnerships to increase access to wearable defibrillator therapy for patients at risk of sudden cardiac arrest.
February 2026: ZOLL Medical Corporation strengthened its digital cardiac care ecosystem by enhancing remote monitoring and patient engagement capabilities for wearable cardioverter defibrillator users, supporting improved clinical outcomes and continuity of care.
Wearable Cardioverter Defibrillators Market Top Companies
Top companies in the wearable cardioverter defibrillators market include Medtronic, ZOLL Medical Corporation, Abbott, Boston Scientific Corporation, LivaNova PLC, Koninklijke Philips N.V., Element Science, and Kestra Medical Technologies, Inc., among others.
Market Impact Assessment
The wearable cardioverter-defibrillator industry is benefiting from increased focus on preventive cardiac care and connected healthcare delivery. Continued expansion of reimbursement coverage improves commercial adoption, while ongoing technological improvements strengthen physician confidence. However, battery performance limitations and patient compliance remain important considerations that manufacturers must address to support wider utilization.
How This Report Supports Business Decisions
This report provides valuable insights for:
- Medical device manufacturers evaluating product development priorities.
- Healthcare providers assessing cardiac monitoring technologies.
- Investors identifying growth opportunities within cardiovascular devices.
- Procurement teams comparing technology adoption strategies.
- Strategy and business development teams monitoring competitive positioning.
- Healthcare technology companies exploring partnerships in remote patient monitoring.
Target Audience
- Medical Device Manufacturers
- Cardiovascular Care Providers
- Hospitals and Cardiac Clinics
- Healthcare Investors
- Procurement Managers
- Product Development Teams
- Digital Health Companies
- Healthcare Distributors
- Regulatory and Market Strategy Teams
- Clinical Research Organizations
Conclusion
The wearable cardioverter defibrillators market continues to gain commercial importance as healthcare systems prioritize early intervention for patients at risk of sudden cardiac arrest. Rising cardiovascular disease prevalence, expanding reimbursement support, and continuous product innovation are expected to sustain long-term market expansion through 2035. Companies that improve device usability, strengthen remote monitoring capabilities, and address battery performance challenges will be better positioned to compete in an increasingly technology-driven cardiac care market. For stakeholders across the healthcare ecosystem, monitoring developments in connected cardiac monitoring and implantable defibrillator technologies will remain essential for capturing future growth opportunities.
